Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer’s ABRYSVO for Infant RSV Prevention Approved in Pregnant Women | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Pfizer’s ABRYSVO for Infant RSV Prevention Approved in Pregnant Women

First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease.

By: Anthony Vecchione

The U.S. FDA approved Pfizer’s ABRYSVO (respiratory syncytial virus vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant women at 32 through 36 weeks gestational age. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains.

The FDA’s decision is based on data from the Phase 3 clinical trial MATISSE, designed to evaluate the efficacy, safety, and immunogenicity of the vaccine against LRTD and severe LRTD due to RSV in infants born to healthy individuals vaccinated during pregnancy.

RSV is a contagious virus and a common cause of respiratory illness worldwide. The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics